MapLight Therapeutics (MPLT) Other Operating Expenses (2024 - 2025)
MapLight Therapeutics (MPLT) reported Other Operating Expenses of -$177.0 million for Q4 2025, down 376.64% on a YoY basis from $64.0 million in Q4 2024, and down 376.64% sequentially from $64.0 million in Q4 2024.
MapLight Therapeutics (MPLT) Other Operating Expenses (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Other Operating Expenses data on file, last reported at -$177.0 million in Q4 2025.
- For the quarter ending Q4 2025, Other Operating Expenses fell 376.64% year-over-year to -$177.0 million; the trailing twelve-month figure through Dec 2025 stood at -$113.0 million (changed N/A YoY), and the FY2025 full-year result was -$177.0 million, changed N/A from the prior year.
- Other Operating Expenses eased to -$177.0 million in Q4 2025, from $64.0 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $64.0 million in Q4 2024 to a low of -$177.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | MapLight Therapeutics | 314.07 Mn | 314.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -177.01 Mn |
| Dec 31, 2024 | 63.99 Mn |